Pulmatrix Ownership
| PULM Stock | USD 2.04 0.04 1.92% |
Shares in Circulation | First Issued 2012-06-30 | Previous Quarter 3.7 M | Current Value 3.7 M | Avarage Shares Outstanding 1.1 M | Quarterly Volatility 1.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pulmatrix |
Pulmatrix Stock Ownership Analysis
The company has price-to-book ratio of 0.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pulmatrix recorded a loss per share of 3.87. The entity last dividend was issued on the 6th of February 2019. The firm had 1:20 split on the 1st of March 2022. Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 24 people. To find out more about Pulmatrix contact Robert Clarke at 781 357 2333 or learn more at https://www.pulmatrix.com.Besides selling stocks to institutional investors, Pulmatrix also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pulmatrix's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pulmatrix's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pulmatrix Quarterly Liabilities And Stockholders Equity |
|
Pulmatrix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pulmatrix is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulmatrix backward and forwards among themselves. Pulmatrix's institutional investor refers to the entity that pools money to purchase Pulmatrix's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hanson Mcclain Inc | 2023-12-31 | 3.0 | Hrt Financial Llc | 2023-09-30 | 0.0 | Renaissance Technologies Corp | 2023-12-31 | 117.3 K | Blackrock Inc | 2023-12-31 | 54.9 K | Sabby Management Llc | 2023-12-31 | 54.2 K | Vanguard Group Inc | 2023-12-31 | 35.1 K | Geode Capital Management, Llc | 2023-12-31 | 24.7 K | State Street Corporation | 2023-12-31 | 13.9 K | Tower Research Capital Llc | 2023-12-31 | 3.6 K | Advisor Group Holdings, Inc. | 2023-12-31 | 276 | Ubs Group Ag | 2023-12-31 | 165 |
Pulmatrix Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmatrix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmatrix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulmatrix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Teofilo Raad over a year ago Acquisition by Teofilo Raad of 34900 shares of Pulmatrix subject to Rule 16b-3 |
Pulmatrix Corporate Filings
8K | 28th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 2nd of January 2024 An amended filing to the original Schedule 13G | ViewVerify |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pulmatrix using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Pulmatrix Stock analysis
When running Pulmatrix's price analysis, check to measure Pulmatrix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmatrix is operating at the current time. Most of Pulmatrix's value examination focuses on studying past and present price action to predict the probability of Pulmatrix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmatrix's price. Additionally, you may evaluate how the addition of Pulmatrix to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Pulmatrix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.87) | Revenue Per Share 1.998 | Quarterly Revenue Growth 0.289 | Return On Assets (0.25) | Return On Equity (0.58) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.